US & Canada Drug Approvals — April 2026
US & Canada Drug
Approvals — April 2026
The FDA approved 2 landmark drugs in April 2026: Orforglipron (the first oral small molecule GLP-1R agonist for obesity) and Lunsotogene parvec-cwha (an AAV gene therapy targeting OTOF for sensorineural hearing loss). Health Canada approved a Semaglutide biosimilar from Dr. Reddy’s for Type 2 diabetes.
2 drugs approved by the FDA — April 2026
Both represent first-in-class or first-of-modality approvals in their respective indication areas. Source: April 2026 monthly report, Table 1.
| Drug | Target | Modality | Indication | Developer | Date |
|---|---|---|---|---|---|
| Lunsotogene parvec-cwha | OTOF | AAV based gene therapy | Hearing Loss, Sensorineural | Regeneron Pharmaceuticals, Inc. | Apr 23 |
| Orforglipron | GLP-1R | Small molecule drug | Obesity; Overweight | Eli Lilly & Co. | Apr 1 |
1 drug approved in Canada — April 2026
A Semaglutide biosimilar for Type 2 diabetes — the first GLP-1R biosimilar approved in Canada. Source: April 2026 monthly report, Table 1.
| Drug | Target | Modality | Indication | Developer | Date |
|---|---|---|---|---|---|
| Semaglutide (Dr. Reddy’s) | GLP-1R | Recombinant polypeptide; Biosimilar | Diabetes Mellitus, Type 2 | Dr. Reddy’s Laboratories Ltd. | Apr 28 |
All three approvals profiled
Orforglipron — first oral small molecule GLP-1R agonist for obesity
Orforglipron is a small molecule drug targeting GLP-1R, developed by Eli Lilly & Co. Approved by the FDA on April 1, 2026 for Obesity and Overweight — the first oral small molecule GLP-1R agonist for obesity in a class historically defined by injectable peptide biologics. With 47 clinical trials and 40 core patents, and a competitive landscape of 770 GLP-1R drugs, this approval marks a structural shift in the obesity treatment paradigm.
GLP-1R · Small molecule · Oral · Obesity · Eli LillyLunsotogene parvec-cwha — OTOF AAV gene therapy for hearing loss
Lunsotogene parvec-cwha is an AAV-based gene therapy targeting OTOF, developed by Regeneron Pharmaceuticals, Inc. It received FDA Accelerated Approval on April 23, 2026 for sensorineural Hearing Loss. OTOF encodes otoferlin, a protein required for synaptic vesicle exocytosis in cochlear inner hair cells — mutations in OTOF cause autosomal recessive deafness (DFNB9), a severe congenital hearing loss with no prior approved therapeutic option beyond hearing aids and cochlear implants.
OTOF · AAV gene therapy · Sensorineural · RegeneronSemaglutide biosimilar (Dr. Reddy’s) — GLP-1R biosimilar for Type 2 diabetes in Canada
Semaglutide from Dr. Reddy’s Laboratories Ltd. is a recombinant polypeptide GLP-1R biosimilar targeting GLP-1R, approved by Health Canada on April 28, 2026 for Diabetes Mellitus, Type 2. This approval extends access to GLP-1R agonist therapy for Canadian patients with Type 2 diabetes through a biosimilar pathway, creating pricing competition relative to originator Ozempic. Combined with the Semaglutide biosimilar approved in India in April 2026 (NATCO Pharma), this signals the beginning of multi-market GLP-1R biosimilar commercialisation.
GLP-1R · Biosimilar · Type 2 diabetes · Dr. Reddy’s · Canada3 signals from the US & Canada April 2026 approval data
Orforglipron: oral route breaks the injectable barrier in GLP-1 obesity therapy
All previously approved GLP-1R agonists for obesity required subcutaneous injection (semaglutide weekly, tirzepatide weekly). Orforglipron’s oral daily dosing removes the injection barrier for the largest therapeutic indication in metabolic medicine — with 47 clinical trials and 40 core patents establishing Eli Lilly’s IP position in this newly validated oral GLP-1R agonist space. The 770-drug GLP-1R competitive field now includes a landmark oral agent for the first time.
Lunsotogene parvec: AAV gene therapy expands into cochlear OTOF mutations
Lunsotogene parvec-cwha’s FDA Accelerated Approval for OTOF-mutation sensorineural hearing loss marks the entry of AAV gene therapy into inner ear cochlear gene correction. OTOF mutations cause DFNB9 — severe congenital deafness with no prior approved therapy. Regeneron’s programme signals the growing addressability of sensory organ genetic disorders via AAV platforms, extending the gene therapy application space beyond CNS and systemic rare diseases into cochlear and potentially other sensory organ targets.
Semaglutide biosimilar approvals in Canada and India signal multi-market GLP-1 access wave
Two Semaglutide biosimilar approvals in April 2026 — Dr. Reddy’s in Canada (April 28) and NATCO Pharma in India (April 20) — mark the beginning of multi-market GLP-1R biosimilar commercialisation. Both are recombinant polypeptide biosimilars targeting GLP-1R for Type 2 diabetes. These approvals signal the progression of GLP-1R agonists from branded biologic-dominated to biosimilar-accessible markets — with access and pricing implications particularly significant in high-diabetes-burden markets like India.
Both April 2026 FDA approvals are first-in-class or first-of-modality landmark events
April 2026 produced two distinct FDA landmark approvals: Orforglipron (first oral small molecule GLP-1R agonist for obesity — first-in-modality within a validated class) and Lunsotogene parvec-cwha (first approved OTOF gene therapy — first-of-target in cochlear gene correction). Both mark genuine therapeutic firsts, reflecting FDA’s continued willingness to use Accelerated Approval and standard review pathways to advance novel modalities for high-unmet-need indications.
US & Canada drug approvals April 2026 — key questions
The FDA approved 2 drugs in April 2026: Orforglipron (a GLP-1R targeting small molecule drug from Eli Lilly for Obesity and Overweight) and Lunsotogene parvec-cwha (an OTOF-targeting AAV gene therapy from Regeneron Pharmaceuticals for sensorineural Hearing Loss).
Orforglipron, a small molecule drug targeting GLP-1R developed by Eli Lilly & Co., was approved by the FDA on April 1, 2026 for Obesity and Overweight — the first oral small molecule GLP-1R agonist to receive FDA approval for obesity.
Lunsotogene parvec-cwha, an AAV-based gene therapy targeting OTOF, developed by Regeneron Pharmaceuticals, Inc., received FDA Accelerated Approval on April 23, 2026 for sensorineural Hearing Loss.
Semaglutide (Dr. Reddy’s), a GLP-1R-targeting recombinant polypeptide biosimilar developed by Dr. Reddy’s Laboratories Ltd., was approved in Canada by Health Canada on April 28, 2026 for Diabetes Mellitus, Type 2.
Lunsotogene parvec-cwha is an AAV (adeno-associated virus)-based gene therapy targeting OTOF (otoferlin), developed by Regeneron Pharmaceuticals, Inc. It received FDA Accelerated Approval on April 23, 2026 for sensorineural Hearing Loss, specifically targeting OTOF gene mutations that cause severe congenital deafness.
Data on this page is sourced from the PatSnap April 2026 monthly pharmaceutical report, Table 1 (drug approvals). Represents a snapshot of available records as of April 2026.